To achieve the vision of a world free of MS, the National MS Society is a driving force of MS research, relentlessly pursuing prevention, treatment and cure. We devote nearly $50 million each year to a spectrum of key initiatives and other projects based on the guiding principles of Speed, Collaboration and Possibilities:
- Speed
Finding expeditious ways to conduct research, forge relationships, bridge barriers and garner resources to propel research forward - Collaboration
Fostering coalitions worldwide with experts in other fields and diseases to make rapid and meaningful progress - Possibilities
Fueling novel ideas, potential therapies, projects and technologies to discover and pursue every avenue that holds promise
Right now, our researchers are developing and testing novel experimental treatments and tissue repair strategies that may soon be in use for MS. Read more about the progress we’ve made and intriguing leads being pursued by MS investigators.
Research Scope and Philosophy
We strive to fund the best, most relevant research in the U.S. and abroad aimed at moving us closer to a world free of MS
Areas of Research Focus
We support more than 440 research grants and training fellowships on a broad range of topics relevant to MS, including immune aspects, nerve tissue repair and myelin biology, clinical trials, rehabilitation, psychosocial issues and health care delivery. We are also pursuing some key areas of emerging opportunity and need, including:
- Targeted Initiatives —Funding vital MS research and care through the Promise: 2010 Initiative and speeding treatments to people with MS through the Fast Forward™ initiative.
- Collaborative MS Research Centers —These special centers combine the expertise of top MS researchers with scientists outside the field of MS who are using cutting-edge technologies to engage in large-scale explorations, gaining from each other’s experience.
- High-Risk Pilot Research —These unique grants fund short-term investigations on new, untested ideas, allowing researchers to quickly determine if their novel ideas are worth pursuing.
- Research on Progressive MS — Although many of the Society’s research studies explore virtually every aspect of MS and more basic aspects of how the nervous system and immune system works, some studies focus specifically on progressive forms of MS.
Recent Research News
MS Trial Alert: Recruiting Nationwide for Study of Copaxone in Patients with First Episode of Acute Optic Neuritis
Nov 05, 2009
Summary: Investigators at sites throughout the United States are recruiting 200 people who have experienced one episode of acute optic neuritis, to determine whether nerve fiber loss can be minimized with administration of glatirmamer acetate (Teva Pharmaceutical Industries) treatment. Optic neuritis is an inflammation of the optic nerve, and often is the first symptom of multiple sclerosis. The study is funded by Teva Pharmaceutical Industries.
Society-Funded Researchers Show that Early Relapses Link to MS Progression
Nov 05, 2009
A group funded by the National MS Society reports that more relapses early in the course of MS were associated with increased disease progression in a study of 2,477 people with MS, but that this effect diminishes over time. Helen Tremlett, PhD, and colleagues (University of British Columbia, Vancouver) report these results in Neurology (2009;73:1616-23).
Flu Vaccines—2009-2010
Nov 03, 2009
Update on flu vaccines, including H1N1 vaccine.
Update on Tysabri and PML: Company Releases Details of Cases and Risks
Oct 29, 2009
According to information released yesterday by Biogen Idec, there have been 24 confirmed cases of PML among people who have used Tysabri after it became available for prescription in July 2006. Some details about the 24 cases are provided.
Results Published from Rituximab Study in Primary-Progressive MS
Oct 29, 2009
A study of intravenous rituximab (Rituxan®, Genentech and Biogen Idec) in 439 people with primary-progressive MS* has shown that the drug did not slow disease progression when compared with inactive placebo, the primary endpoint of the study. However, MRI scans suggested some benefit, and an analysis of subgroups within the study showed significant delays in patients younger than age 51 and with active disease observed on MRI scans. Early results from this OLYMPUS study were originally reported in a press release in 2008, and at the American Academy of Neurology Annual Meeting in 2009, and now Kathleen Hawker, MD (The Ohio State University Medical Center, Columbus) and colleagues have published their complete findings in Annals of Neurology (2009;66[4]:460-471)